they have not asked for a hearing for 3 years. Tribunals are given greater powers and will be able to order delayed discharge of a patient or to recommend granting of leave of absence or transfer to another hospital. They will even be able to order the discharge or transfer of a patient on a restriction order against the Home Secretary's advice. This follows the result of the judgment of the European Court of Human Rights (X v UK) (Cremona-Barbaro 1983) . It is anticipated that the result of all these changes will be an increase in the number of tribunals from about 900 (at present) to nearly 5000 each year. Mental Health Act Commission: A new Commission is to be established as a special health authority. It will have general protective functions for detained patients and will be required to furnish Parliament with a biennial report. Its 70 part-time members will be doctors, nurses, psychologists, social workers, lawyers, and lay people. Teams will probably visit each psychiatric hospital once a year and each of the special hospitals once a month. The Commission will appoint the State doctors to give opinions on consent for treatment and it will be responsible for preparing a code of practice (see also Hamilton 1983 for more details). Consent to treatment: Dr Pamela Taylor outlined the new legislation relating to the giving of consent for mental treatment. In essence there will be three categories of treatment: (1) those requiring consent and a second opinion (e.g. psychosurgery, hormonal implants); (2) those requiring consent or a second opinion (e.g. ECT, long-term psychoactive drugs); (3) those requiring only the psychiatrist's discretion. Consent will have to be formally documented and the psychiatrist will have to certify that the patient is capable of giving consent, a matter which will no doubt cause much future debate (see Taylor  1983 ). The second opinion will come from a doctor appointed by the Mental Health Act Commission and that doctor must consult other non-medical professionals. The startling aspect of the first category (psychosurgery and hormonal implants) is that it applies to informal patients as well as those under compulsory detention, so that a competent consenting patient could have his operation stopped by a State doctor. A new form of stigmatization of the mentally disordered, perhaps? None of these cumbersome and bureaucratic procedures will apply to medication prescribed in the first three months of a patient's detention nor to urgent treatment, nor to other treatments (e.g. behavioural therapy) which are not specified in regulations. Interleukins: new tool in immunology'
JOHN GUNN

Professor of Forensic
Our immune response to antigen depends on a network of interactions between the various leukocytes of the blood and lymphatic systems. Regulation of these interactions has been shown to be mediated, at least in part, by chemical 'messages' secreted by the cells involved. The generic name of 'lymphokines' was initially proposed (Dumonde et al. 1969 ) for these chemical messengers, because the first to be described were produced by antigen-stimulated T-lymphocytes. Similar factors produced by cells of the macrophage/monocyte series have likewise become known as 'monokines'. The practice of naming such factors with acronyms after activities peculiar to various bioassay systems has generated an unsystematic and opaque nomenclature. To try and remedy this, it was proposed that the new title 'interleukin' be applied to factors which appear to be distinct entities in terms of both biological activity and biochemistry (Aarden et al. 1979) . As a start, the first two interleukins were characterized. A factor originally described as 'lymphocyte activating factor', apparently identical with factors known by six other names, was called interleukin 1 (IL-1). IL-1 has a molecular weight of 12-18 Kd, is produced by macrophages and stimulates proliferation and differentiation of T-helper cells. Apart from the overwhelming attraction of such factors for would-be eavesdroppers on intercellular chit-chat, it is apparent from the papers presented at this meeting that interleukins can be used to manipulate lymphocytes in ways which were not previously possible. In particular, the capacity of IL-2 to promote division and maturation of antigen-stimulated T-lymphocytes in vitro, now makes it possible to obtain lines of antigen-specific T-cells. Of even greater interest are the clones of T-cells which can be obtained by diluting the initial suspension of lymphocytes to the point where, on average, only one T-cell is present in each tissue culture well. All the cells in each clone which grows from one of these single cells are of the same functional subtype and all respond to one particular chemical group on the antigen as their antigenic determinant. These new techniques permit the analysis of the functional responses of different subclasses of T-cells to particular antigens with a high degree of precision.
Dr B M Vose (ICI Pharmaceuticals Division, Alderley Park, Macclesfield) described how the attributes of IL-2 could be applied to the study of antitumour properties of lymphocytes isolated from cancer patients. He disaggregated portions of tumours and of equivalent normal tissues obtained from individual patients to provide suspensions of tumour and normal cells for use as 'targets' for the lymphocytes. Lymphocytes obtained from each patient were tested for their ability to kill tumour cells or normal cells from the same patient, tumour cells from other patients, and cells of a tissue-cultured line called K 562.
He wished to distinguish two types of cytotoxic lymphocyte: (1) Natural killer (NK) cells, a population of large granular lymphocytes which lyse a variety of tumour cells and the various tissue-cultured cell lines (notably K 562), both functions being stimulated by interferon; and (2) smaller cytotoxic T-cells which act specifically against autologous tumour cells.
A major problem in studying antitumour activities of lymphocytes is that of identifying a specific antitumour response by T-cytotoxic lymphocytes against the background of broadspectrum cytotoxicity displayed by NK cells. In this study such differentiation was possible because the disaggregated tumour cell targets were lysed far more efficiently by the small tumour-specific cytotoxic T-cells than by the large granular lymphocytes. With any lymphocyte preparation, therefore, the ratio between the number required to kill autologous tumour and the number required to kill K 562 cells gave an indication of the tumour-specific as opposed to the NK activity. NK cells were separable, by density-gradient centrifugation, from the peripheral blood of tumour patients. In addition to their morphological characteristics, they were distinguishable from other lymphocytes in terms of their complement of surface antigens, some of which were characteristic of monocytes (OKMI +ve), others of immature T-lymphocytes (OKT3 -ve) and their ability to bind lentil lectin. When treated with IL-2, some 5% of this cell population proliferated and acquired surface antigens resembling those of mature T-cells (OKM1 -ve, OKT3 +ve), but at the same time retained both their morphology and their widespectrum antitumour activity. By diluting suspensions of such proliferating cells it has been possible to raise clones of NK cells which differ from one another with regard to their ability to kill K 562 cells (Vose & Bonnard 1983) .
Small cytotoxic T-lymphocytes which would specifically lyse autologous tumour cells as opposed to either autologous normal cells or allogeneic tumour cells, and do so more efficiently than NK cells, were found in about 30% of patients (Vose & Bonnard 1982) . These lymphocytes were obtained from peripheral blood, lymph nodes draining tumours, or from the tumours themselves, and appeared to have been activated by tumour antigens for they proliferated when exposed to IL-2. The precursors of these specific cytotoxic antitumour lymphocytes were found to be concentrated up to 6-fold at the site of the tumour as compared with the blood, and the proportion of cytotoxic/ suppressor (OKT8 +ve) cells to helper (OKT4 +ve) cells was also higher in the tumour than in the blood. Stimulation of peripheral blood or tumour-infiltrating lymphocytes with autologous tumour antigen and IL-2 revealed the presence, in some 50-60% of patients, of potential antitumour lymphocytes which had not in fact been activated in vivo by tumour antigens. Many of the resulting cell lines reacted specifically with autologous tumour both by proliferating and by lysing tumour cells. In a few instances lines showed a general activity against cells of a particular histological origin: they would proliferate in response to, but not kill, all squamous cellswhether normal, neoplastic, autologous or allogeneic.
In a recent development of this work, T-cell clones have been derived from these lines. Such clones showed similar behaviour to the lines from which they were derived, in that they specifically lysed autologous tumour cells and proliferated in response to autologous tumour antigen. A question which could be answered with these clones was why lymphocytes from cancer patients, when stimulated with cells from a pool of allogeneic individuals, frequently showed killing activity against autologous tumour. Clones which killed autologous tumour were derived from lymphocytes stimulated in this way. They showed no NK activity (they did not kill K 562 cells) and no activity against any of the cells in the stimulatory pool, showing that they were not reacting to antigens common to pool members and autologous tumour. It seems likely that the allogeneic cells merely stimulate those Tcells which recognize them as foreign to produce IL-2, and so secondarily stimulate proliferation and maturation of the cytotoxic lymphocytes which can recognize tumour antigens.
In surveying the possible therapeutic application of IL-2-stimulated lines and clones of anti-tumour lymphocytes, Dr Vose warned that (a) viruses or mycoplasms might be introduced into the recipient together with the cultured lymphocyte lines; and (b) the lymphocyte lines or clones might themselves have become neoplastic in culture.
Another immunosurveillance mechanism, that by which T-lymphocytes appear to protect those of us who have been infected with EB virus from excessive proliferation of our B-lymphocytes, was introduced by Dr A Rickinson (Bristol University). When B-lymphocytes from an individual who is immune to EB virus are grown in vitro, in the absence of T-lymphocytes, rapidly proliferating clones of the EB-infected Blymphocytes emerge. T-cells from this same individual will prevent emergence of these clones, but this suppressive effect is lost if the drug cyclosporin A, a specific T-cell suppressant, is present in the culture during the first few days. However, if IL-2 as well as cyclosporin A is present, then again the emergence of B-cell clones is prevented. It appears that EB-infected B-cells are prevented from proliferating by clones of cytotoxic T-cells which recognize EB antigens. The precursors of these cytotoxic T-cells, however, will not proliferate and differentiate into effector cytotoxic cells until they have received a signal, in the form of IL-2 produced by T-helper cells which have also recognized the EB-infected cells. Some part of this latter process is inhibited by cyclosporin A, but the signal to the cytotoxic T-cell precursors can be replaced by exogenous IL-2.
Lines of T-cells which will lyse EB-infected Bcells can be obtained by treating regressing cultures of lymphocytes from EB-immune individuals with IL-2. These T-cytotoxic cell lines will lyse EB-infected B-cells of other individuals with whom they share a particular allotype at the HLA-A or HLA-B histocompatibility loci. It appears that the T-cytotoxic cells must recognize the HLA antigen molecule in addition to the EBviral antigen, for their cytotoxic effect is inhibited by monoclonal antibody against the shared HLA antigen.
The ability to produce a clone of T-cytotoxic cells, all members of which react with a particular EB antigen + HLA antigen combination, has revealed a most interesting heterogeneity within what, by serological tests, are homogeneous HLA allotypes. A particular clone of T-cytotoxic cells known to recognize, for example, HLA-A2 antigen in combination with EB antigen, when added to cultures of EB-infected HLA-A2 +ve B-cells derivedfrom various donors, causes extensive cell-lysis in some, little or no cell-lysis in others and intermediate levels in yet others. EBinfected B-cells which are not lysed by a lymphocyte line specific for one of its HLA antigens, may be efficiently lysed by a line which responds to another of its HLA antigens in combination with EB antigen. The variation does not, therefore, reflect any difference in susceptibility to lysis of the various EB-infected B-cells. This implies that HLA-A2 antigen, together with other HLA-A and HLA-B antigens for which similar results were obtained, exists in various subtypes, presumably with minor antigenic variations which are distinguishable by T-cytotoxic cells but not by antisera. It is of interest, too, that the cytotoxic activity of cells which are cloned, and therefore presumably all equipped with identical antigen-receptor sites, was graded rather than all or none. This suggests that T-cytotoxic cells can give a graded cytotoxic response which is dependent on how well their receptor site fits the antigenic determinant.
The availability of antigen-specific lines of cytotoxic T-cells has also revealed that some HLA antigen allotypes can, as far as cytotoxic Tcells are concerned, simulate another HLA allotype + viral antigen. For instance, it was initially puzzling to find that a T-cell line which killed EB-infected HLA-B8 cells, also killed EB infected cells of the HLA allotypes BW62, BW35 and BW44. Subsequently it was found that this line killed cells of these three allotypes even when they were not EB-infected, and it now appears that these particular T-cytotoxic cells see BW62, BW35 and BW44 as if they were B8 + EB antigen.
Recognition of viral antigens by T-cells was also the basis of the paper presented by Dr J Lamb (ICRF Human Tumour Immunology Group, School of Medicine, University College London), in this case the recognition of influenza A antigens by T-helper lymphocytes. However, the topic was not the antiviral activity but the mechanisms of tolerance whereby the immune system is inhibited from mounting a normal immune response to specific antigens, notably the 'selfr antigens of which the body is composed. Two mechanisms by which antigen induces tolerance, either by repeated exposure to suboptimal doses or by a single exposure to a supraoptimal dose, were described some years ago by Mitchison (1971) . This paper was concerned with the cellular mechanisms by which the latter type of tolerance might be brought about (Lamb & Zanders 1984) . Again the value of IL-2 lay in the homogeneous response to a particular fragment of the HA-1 molecule of influenza virus which is shown by a clone of cells all bearing identical receptors for that antigen.
From the blood of human subjects known to respond to influenza A virus, clones of T-cells were obtained by culturing at high dilutions in the presence of irradiated autologous peripheral blood leucocytes (PBL, which act as 'feeder cells', and 'antigen-presenting cells'), viral antigen and IL-2. These clones react to viral peptides, in the presence of irradiated autologous PBL, by proliferating. Prior exposure of such a clone to high concentration of the antigen (more than 3 pg/ml), either in the presence or absence of antigen-presenting cells, did not provoke the cells to proliferate. Moreover they failed to proliferate if subsequently (during the next 7 days) exposed to the normal stimulatory dose of antigen in the presence of antigen-presenting cells. This unresponsiveness, or tolerance, was antigenspecific: it was induced only by the specific peptide to which the clone normally responded. It did not reflect death or some general anergic state of the cells, for these tolerant cells could be induced by IL-2 to proliferate. This antigenspecific immune tolerance seemed to be a property of the T-helper cells themselves; it could be induced in the absence of T-suppressor cells and was not overcome by increasing either the numbers of irradiated antigen-presenting cells in the clonal cultures or the concentration of IL-2. Furthermore, when a clone specific for one viral peptide was tolerized and then mixed with another, non-tolerized clone specific for a second viral peptide, cells in the mixed culture remained tolerant to the first peptide but would still proliferate if challenged with the second. This shows that the states of tolerance or antigen reactivity are intrinsic to the lymphocytes themselves and are not mediated by nonspecific inhibitory or stimulatory agents.
Functionally it was found that not only had tolerized T-helper cells lost their proliferative response to their specific antigen, but they had also lost the property, after which they are named, of helping B-lymphocytes to produce antibodies to this same antigen. However, the concentration of antigen required to make Thelper clones lose their helper function was much lower than that which caused them to lose their proliferative response to antigen. This suggests that antigen stimulates proliferation of T-helper cells by a different mechanism from that by which it induces these cells to differentiate into effective 'helpers'.
Of particular interest concerning the elusive antigen recognition site of the T-lymphocyte, was the observation that a cell-surface antigen called T3 disappeared when tolerance was induced by high concentrations of influenza antigen. Furthermore, treatment of cloned T-helpers with antibody to the T3 antigen both caused a disappearance of this antigen from the cell surface and induced tolerance in the clone as regards its helper function. These results, together with previous observations by Meuer et al. (1983) , suggest that the T3 antigen is linkeed functionally, probably by virtue of a structural linkage, with the antigen-specific receptor site of the T-helper lymphocyte. According to this view antigen excess would induce tolerance by causing a loss of the T3/antigen-receptor complex from the surface of these cells. If this is so, the question which next arises is why this loss is so long-term, when many other molecules of the lymphocyte surface are replaced within hours of being lost as a result of treatment with antibody against them.
All three papers illustrated most clearly the value of the technical advance of being able to produce lines and clones of T-lymphocytes with the aid of IL-2: previously insoluble problems in immunology are rendered amenable to experiment. Clonal T-lymphocytes are very specific and homogeneous and, like monoclonal antibodies, will surely be among the most important tools in elucidating the molecular bases of cellular phenomena. 
